CareDx Advances Global Transplant Patient Care at ESOT Congress 2023
14.9.2023 09:00:00 EEST | Business Wire | Press release
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 2023 European Society for Organ Transplantation (ESOT) Congress taking place September 17-20, 2023, in Athens, Greece.
The latest scientific advances in global transplantation using CareDx’s AlloSeq cfDNA testing solutions are being showcased across eleven abstracts, including four posters, two moderated e-posters, one focus group, and five oral presentations. CareDx is hosting an educational symposium for medical professionals demonstrating the clinical utility of AlloSeq cfDNA. AlloSeq cfDNA is offered to European and other customers outside of the United States, to detect donor-derived cell-free DNA (dd-cfDNA) for the surveillance of allograft rejection risk in solid organ transplant patients.
“We are proud to attend ESOT Congress 2023, a preeminent European transplant conference, and share the latest data demonstrating the use of AlloSeq cfDNA,” said Reg Seeto, CEO and President of CareDx. “Through our partners and work with transplant centers internationally, we have made excellent progress in improving access to AlloSeq cfDNA for the benefit of organ transplant patients globally.”
AlloSeq cfDNA data being presented at ESOT Congress 2023
|
Abstract Title |
|
KIDNEY |
|
|
|
|
|
|
|
|
HEART |
|
|
|
LUNG |
|
|
MULTI-ORGAN |
|
“It is gratifying seeing the impact of dd-cfDNA on clinical practice and patient care. We’ve seen how the information from AlloSeq cfDNA testing not only helps clinicians in their decision-making, but also empowers transplant recipients, providing them control, understanding, and greater peace of mind on the status of their transplanted organ,” Dr. Thomas Schachtner, Transplant Specialist, University Hospital Zurich, Switzerland.
CareDx will review the latest data on AlloSeq cfDNA during an ESOT Congress 2023 Industry Satellite Symposium titled, “Adopting dd-cfDNA for Solid Organ Surveillance: Raising the Standards of Transplant Care.” The symposium will be held live and streamed virtually on ESOT’s Congress platform on Sunday, September 17, 2023. Dr. Titte Srinivas, Chief Medical Officer at CareDx and Dr. Georg Böhmig, Associate Professor at the Medical University Vienna, Austria, will moderate the session. Speakers include:
- Maarten Naesens, MD, PhD, Clinical Director, Professor of Nephrology and Renal Transplantation, University Hospitals Leuven, Belgium
- Alexandre Loupy, MD, PhD, Professor of Nephrology and Epidemiology, Necker Hospital, PITOR (Paris Institute for Transplantation & Organ Regeneration), France
- David Cucchiari, MD, PhD, Associate Professor of Nephrology, Hospital Clínic Barcelona, Catalonia, Spain
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, and with a European headquarter office in Stockholm, Sweden, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with the Company’s AlloSeq cfDNA solutions and its participation at the 2023 ESOT Congress. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of its AlloSeq cfDNA solutions, or its participation at the 2023 ESOT Congress; general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed by CareDx with the SEC on February 27, 2023, the quarterly report on Form 10-Q for the quarter ended March 31, 2023 filed by CareDx with the SEC on May 10, 2023, the quarterly report on Form 10-Q for the quarter ended June 30, 2023 filed by CareDx with the SEC on August 8, 2023, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230913528887/en/
Contact information
CareDx, Inc.
Media Relations
Anna Czene
818-731-2203
aczene@caredx.com
Investor Relations
Greg Chodaczek
investor@caredx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Align Technology Prevails in China Patent Infringement Action Against Angelalign12.8.2026 03:47:00 EEST | Press release
Align Technology, Inc. ("Align") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, today announced that the Jinan Intermediate People's Court in China issued a judgment in favor of Align in a patent infringement action against Angelalign Technology's operating subsidiaries in China ("Angel") (Hong Kong Stock Exchange: 6699.HK). In September 2025, Align filed a patent infringement action against Angel in the Jinan Intermediate People's Court, asserting Align’s patent related to extraction-gap-closure technology (CN113693748B). On August 10, 2026, the Jinan Intermediate People's Court issued a first-instance judgment finding that Angel's use of its MasterForce biomechanical simulation system and ATreat digital orthodontic treatment design system to generate A7 and A7 Speed premolar extraction treatment solutions infringes Align's patent rights. The court further found that the related aligner products m
Entrepreneurs Invited to Apply for 2027 SPIE Startup Challenge11.8.2026 21:40:00 EEST | Press release
Entrepreneurs around the world are invited to apply for a chance to pitch their optics or photonics technologies or products to a panel of expert judges at the 17th annual SPIE Startup Challenge. SPIE, the international society of optics and photonics, holds the competition at Photonics West every January, with multiple teams walking away with cash prizes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260811090450/en/ Coalesenz won first prize for their hand-held, point-of-care coagulation analyzer at the SPIE Startup Challenge at Photonics West in January 2026. More than a simple pitch competition, the SPIE Startup Challenge is an entry point into the community of high-tech business development of new products in healthcare and deep tech, with an audience of experienced photonics innovators and investors. Cash prizes of $10,000, $5,000, and $2,500 are provided by Startup Challenge Founding Partner Jenoptik. Also given is t
The Aga Khan Museum Welcomes Prince Aly Muhammad Aga Khan and Saira Bhojani to its Board of Directors11.8.2026 18:30:00 EEST | Press release
The Aga Khan Museum is pleased to announce the appointment of Prince Aly Muhammad Aga Khan and Saira Bhojani to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260811597825/en/ Prince Aly Muhammad Aga Khan, board member, Aga Khan Museum Prince Aly Muhammad Aga Khan joins the Board with a deep commitment to arts and culture. He brings an international outlook shaped by working with the Aga Khan Foundation and Aga Khan Music Programme. Committed to advancing pluralism and cultural dialogue, Prince Aly brings a fresh perspective that will help guide the Museum as it continues to evolve, engage new audiences, and expand its impact both in Canada and internationally. Prince Aly is the son of His Late Highness Prince Karim Aga Khan IV and brother of His Highness Prince Rahim Aga Khan V. Joining him on the Board is Saira Bhojani, Partner at Torys LLP and one of Canada's leading tax lawyers. Ms. Bhojani is wid
Mouser Explores the Future of Quantum Computing and Its Potential to Transform Engineering11.8.2026 17:48:00 EEST | Press release
Mouser Electronics, Inc., the authorized global distributor with the newest electronic components and industrial automation products, today announced the latest installment of its Empowering Innovation Together (EIT) technology series, A Quantum Leap in Computer Processing. This installment explores the emerging field of quantum computing and examines how the principles of quantum mechanics could unlock new computational capabilities for solving problems that remain difficult for conventional computing architectures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260811222432/en/ Explore how quantum computing could help engineers address problems too complex for traditional systems. Unlike traditional computers, quantum computers leverage quantum-mechanical phenomena, such as superposition, entanglement, and interference, to perform calculations in fundamentally different ways. While today's quantum systems still face challe
Andersen Global Expands Legal Capabilities with Beech Incorporated11.8.2026 16:30:00 EEST | Press release
Andersen Global enters into a Collaboration Agreement with Beech Incorporated, a legal firm based in South Africa, broadening its legal capabilities in the region. Beech Incorporated provides legal and regulatory services to the mining, renewable energy, infrastructure, oil and gas sectors, specializing in mergers and acquisitions, commercial, project financing, health, safety and environmental, employment, and compliance matters. The firm’s multidisciplinary team advises clients across the full project lifecycle—from development and financing to operations and stakeholder engagement—and is recognized as a leading legal firm by publications including Chambers and Partners and The Legal 500. “Our approach is built on understanding the industries we serve at a practical level and providing practical, actionable advice to clients operating in complex regulatory environments,” said Warren Beech, CEO of Beech Incorporated. “By working alongside the member and collaborating firms of Andersen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom